Sodium-glucose cotransporters inhibitors (SGLT2-i) and GLP-1 receptor agonists (GLP1-
RA) are glucose-lowering drugs that are proved to reduce the cardiovascular (CV) risk in …

Multiple types of renin-angiotensin system (RAS) blockers exist, allowing interference with
the system at the level of renin, angiotensin-converting enzyme, or the angiotensin II …

Background Angiotensinogen is the sole precursor of angiotensin peptides and has a key
role in the pathogenesis of hypertension. Zilebesiran, an investigational RNA interference …

Blood pressure management involves antihypertensive therapies blocking the renin-
angiotensin system (RAS). Yet, it might be inadequate due to poor patient adherence or the …

Despite the availability of various therapeutic classes of antihypertensive drugs,
hypertension remains poorly controlled, in part because of poor adherence. Hence, there is …

Background and Purpose Small interfering RNA (siRNA) targeting liver angiotensinogen
lowers blood pressure, but its effects in hypertensive diabetes are unknown. Experimental …

The concept of local formation of angiotensin II in the kidney has changed over the last 10–
15 years. Local synthesis of angiotensinogen in the proximal tubule has been proposed …

Accurate assessment of the glomerular filtration rate (GFR) is crucial for researching kidney
disease in rats. Although validation of methods that assess GFR is crucial, large-scale …

AGT (angiotensinogen) is the unique substrate of the renin-angiotensin system. While many
cells synthesize AGT, studies in mice have demonstrated that plasma AGT is predominantly …

RNA-based therapies are currently used for immunisation against infections and to treat
metabolic diseases. They can modulate gene expression in immune cells and hepatocytes …